Evolution of SARS-CoV-2 neutralizing antibody in an HIV-positive patient with COVID-19
Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
Date Issued
2021-04-21
Abstract
We presented the clinical course and immune responses of a well-controlled HIV-positive patient with COVID-19. The clinical presentation and antibody production to SARS-CoV-2 were similar to other COVID-19 patients without HIV infection. Neutralizing antibody reached a plateau from 26th to 47th day onset but decreased on 157th day after symptoms.
Subjects
Antiretroviral therapy; Coronavirus; Enzyme-linked immunosorbent assay (ELISA); Plaque reduction assay; Severe acute respiratory syndrome
SDGs
Other Subjects
abacavir; dolutegravir; lamivudine; neutralizing antibody; immunoglobulin G; neutralizing antibody; virus antibody; adult; antibody production; antiretroviral therapy; Article; case report; clinical article; controlled study; coronavirus disease 2019; disease course; enzyme linked immunosorbent assay; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; male; virus load; virus neutralization; complication; enzyme linked immunosorbent assay; Human immunodeficiency virus infection; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; Enzyme-Linked Immunosorbent Assay; HIV Infections; Humans; Immunoglobulin G; SARS-CoV-2
Type
journal article